Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.
Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.
复制标题
DOI:
10.1371/journal.pone.0036530
复制
发表时间:
2012
期刊:
影响因子:
3.7
通讯作者:
Hayes DN
中科院分区:
文献类型:
--
作者:
Wilkerson MD;Yin X;Walter V;Zhao N;Cabanski CR;Hayward MC;Miller CR;Socinski MA;Parsons AM;Thorne LB;Haithcock BE;Veeramachaneni NK;Funkhouser WK;Randell SH;Bernard PS;Perou CM;Hayes DN
Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well understood, limiting progress in therapy development and research. LAD intrinsic molecular subtypes are a validated stratification of naturally-occurring gene expression patterns and encompass different functional pathways and patient outcomes. Patients may have incurred different mutations and alterations that led to the different subtypes. We hypothesized that the LAD molecular subtypes co-occur with distinct mutations and alterations in patient tumors. The LAD molecular subtypes (Bronchioid, Magnoid, and Squamoid) were tested for association with gene mutations and DNA copy number alterations using statistical methods and published cohorts (n = 504). A novel validation (n = 116) cohort was assayed and interrogated to confirm subtype-alteration associations. Gene mutation rates (EGFR, KRAS, STK11, TP53), chromosomal instability, regional copy number, and genomewide DNA methylation were significantly different among tumors of the molecular subtypes. Secondary analyses compared subtypes by integrated alterations and patient outcomes. Tumors having integrated alterations in the same gene associated with the subtypes, e.g. mutation, deletion and underexpression of STK11 with Magnoid, and mutation, amplification, and overexpression of EGFR with Bronchioid. The subtypes also associated with tumors having concurrent mutant genes, such as KRAS-STK11 with Magnoid. Patient overall survival, cisplatin plus vinorelbine therapy response and predicted gefitinib sensitivity were significantly different among the subtypes. The lung adenocarcinoma intrinsic molecular subtypes co-occur with grossly distinct genomic alterations and with patient therapy response. These results advance the understanding of lung adenocarcinoma etiology and nominate patient subgroups for future evaluation of treatment response.
登录
查看更多内容
影响因子:
50.3
作者:
Carretero J;Shimamura T;Rikova K;Jackson AL;Wilkerson MD;Borgman CL;Buttarazzi MS;Sanofsky BA;McNamara KL;Brandstetter KA;Walton ZE;Gu TL;Silva JC;Crosby K;Shapiro GI;Maira SM;Ji H;Castrillon DH;Kim CF;García-Echeverría C;Bardeesy N;Sharpless NE;Hayes ND;Kim WY;Engelman JA;Wong KK
通讯作者:
Wong KK
影响因子:
8
作者:
Chitale, D.;Gong, Y.;Taylor, B. S.;Broderick, S.;Brennan, C.;Somwar, R.;Golas, B.;Wang, L.;Motoi, N.;Szoke, J.;Reinersman, J. M.;Major, J.;Sander, C.;Seshan, V. E.;Zakowski, M. F.;Rusch, V.;Pao, W.;Gerald, W.;Ladanyi, M.
通讯作者:
Ladanyi, M.
影响因子:
28.2
作者:
Kim ES;Herbst RS;Wistuba II;Lee JJ;Blumenschein GR Jr;Tsao A;Stewart DJ;Hicks ME;Erasmus J Jr;Gupta S;Alden CM;Liu S;Tang X;Khuri FR;Tran HT;Johnson BE;Heymach JV;Mao L;Fossella F;Kies MS;Papadimitrakopoulou V;Davis SE;Lippman SM;Hong WK
通讯作者:
Hong WK
影响因子:
82.9
作者:
Beer, DG;Kardia, SLR;Hanash, S
通讯作者:
Hanash, S
影响因子:
3.7
作者:
Bryant CM;Albertus DL;Kim S;Chen G;Brambilla C;Guedj M;Arima C;Travis WD;Yatabe Y;Takahashi T;Brambilla E;Beer DG
通讯作者:
Beer DG